Customized medication therapy improves patient outcomes in as little as 90 days. These are improvements over national averages for standard practices. Rapid improvement in outcomes drive significant savings for payors, healthcare systems, and self-insured employers.
Our treatment program for Secondary Hyperparathyroidism (SHPT) brings 99% of patients under control within 60 days.
ICG combines patient clinical data with clinical practice guidelines, the best data about current medications, and clinical algorithms based on pharmacological science to produce the optimal medication therapy for each individual patient..
CeutiCare © ALL RIGHTS RESERVED.